Navigation Links
Perrigo Partner Teva Receives Final OTC Approval for Sales and Distribution of Fexofenadine HCl 60 mg and 180 mg Tablets
Date:4/13/2011

ALLEGAN, Mich., April 13, 2011 /PRNewswire/ -- Perrigo (Nasdaq: PRGO;TASE) today announced that its partner, Teva Pharmaceutical Industries, Ltd. (Nasdaq: TEVA), has received final OTC approval to sell and distribute fexofenadine HCl 60 mg and 180 mg tablets; the generic equivalents of Sanofi-Aventis' Allegra 60 mg and 180 mg products.  Teva has had Rx approval for these products, and Teva and Sanofi-Aventis have settled their Paragraph IV/Hatch-Waxman litigation relating to the Allegra brand family of products.

Allegra 60 mg and 180 mg tablets are indicated for the temporary relief of symptoms associated with indoor and outdoor allergies.  Chattem, Inc., a wholly-owned U.S. subsidiary of Sanofi-Aventis, launched Allegra 60 mg and 180 mg tablets in retail stores on March 3, 2011 as part of their Rx to OTC switch of the Allegra brand.  Perrigo expects to begin distributing fexofenadine 60 mg and 180 mg tablets to its wholesale and retail customers under their store brand labels immediately.

Perrigo's Chairman and CEO Joseph C. Papa stated, "This is a particularly important example of Perrigo's strategic focus and execution of making quality healthcare more affordable to American consumers by introducing new store brand versions of important Rx-to-OTC switch products.  We look forward to working with our retail and wholesale customers to grow these new store brand products as important components in their retail allergy categories."

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription pharmaceuticals, nutritional products, infant formula, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Australia, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 27, 2009, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Announces Approval for Over-the-Counter Childrens Cetirizine Oral Solution
2. Perrigo and Partner Cobrek Confirms Filing for Generic Version of Evoclin(R) and Announcement of Lawsuit by Stiefel
3. Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350
4. Perrigo Confirms Filing for Generic Version of Mens Rogaine(R) Foam
5. Perrigo Company Will Release First Quarter Fiscal 2010 Results on November 2, 2009
6. Perrigo Company Announces Dividend Increase
7. Perrigo Company Announces Quarterly Dividend
8. Perrigo Company Will Release Second Quarter Fiscal 2010 Results on February 2, 2010
9. Perrigo Company to Present at the 28th Annual J.P. Morgan Healthcare Conference
10. Perrigo Company To Present at the Sidoti Emerging Growth Conference
11. Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... The pen needles market is projected to ... billion in 2016, growing at a CAGR of 11.2% ... Over the years, the pen needles market has witnessed ... growing demand for safety injections in the healthcare industry. ... pen needles with an aim to reduce pain, increase ...
(Date:12/6/2016)... , Dec. 6, 2016  Nearly 30 million people ... from the epidemic of diabetes. 1 However, nearly ... elevated glucose levels (hyperglycemia) and significant glucose variability. 2 ... complications, including cardiovascular events. If left untreated, hyperglycemia can ... eye disease or blindness. 3 As ...
(Date:12/6/2016)... Fla. , Dec. 6, 2016 With opioids commonly ... newcomer in the prescription drug market that has led to nationwide ... approximately seven to eight times stronger than heroin or morphine, resulting ... ... Suzanne Smolkin , vice president, clinical operations, Behavioral Health for HMC ...
Breaking Medicine Technology:
(Date:12/7/2016)... , ... December 07, 2016 , ... One of two ... of the securement tape is painful for her. "This is why the co-inventor and ... heads," she said. , They then created a prototype of the patent-pending AV-AIR, a ...
(Date:12/7/2016)... ... ... Sharon Kleyne, host of the nationally syndicated radio program, The Sharon Kleyne ... declared on her radio program in November 2016 the need to educate people about ... leaders in corporate America, they are trying to take advantage of successful algorithms and ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... is condemning "scam operations" carried out by unethical locksmith companies and is urging ... to a halt. According to Texas Premier Locksmith, these fraudulent locksmith services take ...
(Date:12/7/2016)... ... December 07, 2016 , ... Gensuite ... Brilliance Awards under the Best New Product Launch category. Gensuite’s entry on their ... experience. , BOC Global Events & Training Group is a professional event and ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... “Tomorrow Trump ... Donald Trump bringing greatness back to the presidency and to America. “Tomorrow Trump Goes ... to do as much as she can for this country. , Nancy attributes her ...
Breaking Medicine News(10 mins):